NEW YORK, Feb. 15, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Renovaro Biosciences Inc. ("Renovaro" or the "Company") (NASDAQ: RENB). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Renovaro and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On February 13, 2024, Hindenburg Research ("Hindenburg") published a short report on Renovaro, alleging, among other things, that in the months leading up to the vote on Renovaro's merger with GEDi Cube, "Renovaro enlisted stock promoters, including one previously sanctioned by the SEC, to hype up the GEDi deal and pump shares to retail investors."
Following publication of the Hindenburg report, Renovaro's stock price fell $1.44 per share, or 42.86%, to close at $1.92 per share on February 13, 2024, damaging investors.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
![](https://rt.prnewswire.com/rt.gif?NewsItemId=DC38366&Transmission_Id=202402151800PR_NEWS_USPR_____DC38366&DateId=20240215)
Share this article